logo-loader

LexaGene Holdings closes on C$13.29M in financing to build inventory and expand sales

Last updated: 11:50 09 Sep 2020 EDT, First published: 10:59 09 Sep 2020 EDT

LexaGene Holdings Inc. - LexaGene Holdings closes on C$13.29M in financing to build inventory and expand sales
CEO Dr Jack Regan says the financing will transform the company from strictly R&D to one that supports manufacturing and sales

LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) has closed on a bought-deal financing scheme that raised about C$13.29 million. 

The molecular diagnostics company that develops genetic analyzers for rapid pathogen detection said it intends to use the net proceeds to build inventory to meet anticipated demand, expand its sales and marketing efforts and for general corporate purposes.

LexaGene issued 15,640,000 units in an over-allotment at C$0.85 apiece, with each unit consisting of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one share for C$1.10.

READ: LexaGene Holdings hires contract manufacturer LaunchWorks to support MiQLab launch

The offering was conducted by Canaccord Genuity Corp and Industrial Alliance Securities Inc. On closing, the company issued the underwriters an aggregate of 1,094,800 broker warrants, entitling the holder to purchase one share for C$1.10.

“Over the last four years, LexaGene has constantly been gaining momentum,” said CEO Dr Jack Regan in a statement Wednesday. “This financing will allow us to complete the transformation of going from strictly an R&D company, to one that is supporting manufacturing and sales. This is a very exciting time to be part of LexaGene as we look to make an impact on multiple market verticals.”

LexaGene develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.

Its MiQLab analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

12 hours, 20 minutes ago